^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

Abstract 5212: The benefits of Didox in triple negative breast cancer treatment targeting mutant p53

Published date:
05/15/2020
Excerpt:
However, it has been identified that 80% of TNBC samples carry TP53 (tumor protein p53) mutations...Our current study shows that Didox alone or in combination with DOXO downregulates mutant p53 protein levels in the mutant p53 TNBC cell lines MDA-MB 468, MDA-MB 231 and BT-20. This effect is notably absent in breast cancer cell lines with wild-type p53, including MCF7, A3B5 and ZR751, where p53 successfully acts as a tumor suppressor allowing for cell cycle arrest or apoptosis after DNA damage.
DOI:
10.1158/1538-7445.AM2020-5212